Episode Highlights:The industry and operational challenges facing DCT adoption.How inconsistent nomenclature has contributed to widespread misunderstanding of DCT, and how misnomers have slowed adoption.The challenge of change management and how clarity and infrastructure can be an antidote.How DCT can help boost minority representation in clinical trial research, and why shifting those numbers requires time. How sponsors can get started with DCT and what they need to consider.Why organizational fit is critical and how to assess it.Why it’s so important to talk with the patients and understand the challenges they face.Why DCT and patient-centric approaches so often go hand-in-hand.How patient engagement is changing, and why clinical trials need to adapt to that.How sites have been forgotten as stakeholders and why they’re still central to clinical development.Resources:www.archemedx.comConversations in Clinical Trial Readiness serieswww.revelesclinical.comwww.linkedin.com/in/klritchwww.linkedin.com/in/r-kes-starling-rph-mba-9996214/www.clinicaltrialpodcast.comReveles’ Decentralized Clinical Trial Grader: https://form.typeform.com/to/RhOpipVQhttps://www.linkedin.com/company/reveles-clinical-services